Introduction
============

In all animal species, in which the cholesterol precursor 7-dehydrocholesterol is exposed to UV-B, the secosteroid vitamin D~3~ is formed in a non-enzymatic reaction ([@B20]). At a sunny day with an UV index of 3 or higher humans can produce vitamin D~3~ in their unprotected skin ([@B26]). However, today's lifestyle with predominant indoor activity and textile coverage outdoors as well as seasonal variations in sun intensity at latitudes higher than 30°N or lower than 30°S often prevents endogenous vitamin D~3~ synthesis and makes the molecule for a large proportion of the human population an essential micronutrient, i.e., a true vitamin, that needs to be taken up by diet or supplementation with pills ([@B3]; [@B6]). Interestingly, more than 100 years ago a sunshine cure leading to endogenous production of vitamin D~3~ was used as an efficient therapy of the children's bone malformation disease rickets as well as of the infectious disease tuberculosis ([@B25]; [@B19]).

Vitamin D~3~ itself is biologically inert, but hydroxylation at carbon 25 of its side chain into 25-hydroxyvitamin D~3~ and further hydroxylation at carbon 1 within its A-ring results in the active metabolite 1,25(OH)~2~D~3~. As a lipophilic molecule 1,25(OH)~2~D~3~ easily passes through biological membranes and binds with high-affinity (k~D~ 0.1 nM) to the transcription factor VDR, which is primarily located in the nucleus ([@B21]). This explains why vitamin D~3~ has via its metabolite 1,25(OH)~2~D~3~ major effects on the transcriptome and the resulting proteome of VDR-expressing cell types. Proximal tubule cells of the kidneys are the main production site of the circulating endocrine hormone 1,25(OH)~2~D~3~, but for para- and autocrine use the molecule is also formed in monocytes, macrophages and dendritic cells of the innate immune system, osteoblasts within bones and keratinocytes of the skin ([@B24]).

When 250--500 million years ago some animal species left the ocean and had to develop a stable calcium-based skeleton, 1,25(OH)~2~D~3~ developed to a nuclear hormone that, via its receptor, took over the role as main regulator of calcium homeostasis ([@B4]). Within the same evolutionary time span, the immune system of vertebrates further evolved and the vitamin D endocrine system acquired a role in its regulation, in order to mediate a more efficient protection against infectious diseases, such as tuberculosis. Tuberculosis is caused by the intra-cellular bacterium *Mycobacterium tuberculosis*, the proliferation of which within macrophages is inhibited by vitamin D ([@B45]). Moreover, after vitamin D treatment monocytes and macrophages recognize bacterial pathogens more efficiently via pattern-recognition receptors, such as toll-like receptors ([@B28]). A key player in the anti-microbial effects of 1,25(OH)~2~D~3~ is the protein cathelicidin, which is encoded by the primary vitamin D target gene *CAMP* and rapidly destroys the lipoprotein membranes of microbes ([@B18]). Transcriptome-wide analysis indicated that in human monocytes a few hundred additional genes respond to vitamin D ([@B48]). This review will present the epigenome- and transcriptome-wide response of the monocytic cell line THP-1 to vitamin D as a paradigm for distinguishing four regulatory scenarios of vitamin D target genes.

The Transcription Factor VDR
============================

Larger amounts of VDR protein are found in intestine, kidneys, skin, parathyroid gland and pituitary gland, but also most of the other 400 tissues and cell types of the human body, including those of the innate and adaptive immune system, show some VDR expression^[1](#fn01){ref-type="fn"}^. Since transcription factors, such as VDR, do not need high expression levels for their effective function, it can be assumed that most human tissues are sensitive to vitamin D.

Like other members of the nuclear receptor superfamily, VDR carries a structurally conserved ligand-binding domain, the inner surface of which forms a ligand-binding pocket that snugly encloses the molecule 1,25(OH)~2~D~3~ ([@B33]). In turn, VDR interacts via the outer surface of the ligand-binding domain with other nuclear proteins, such as histone acetyltransferases ([@B23]), co-repressors contacting histone deacetylases ([@B42]), lysine demethylases ([@B41]) and chromatin remodelers ([@B61]). These proteins either form large protein complexes with VDR or their genes are primary or secondary targets of vitamin D.

The special feature of transcription factors, such as VDR, is their ability to bind in a sequence-specific fashion to genomic DNA. VDR preferentially binds as a heterodimeric complex with its partner nuclear receptor retinoid X receptor (RXR) to a direct repeat of the hexameric motif A/GGG/TTC/GA spaced by three nucleotides, which is referred to as a DR3-type response element ([@B9]; [Figure 1](#F1){ref-type="fig"}). The genome-wide binding pattern of VDR, its so-called cistrome, was determined by the method chromatin immunoprecipitation combined with massive parallel sequencing (ChIP-seq). In human the VDR cistrome had been figured out in lymphocytes ([@B43]), colorectal cancer cells ([@B31]), hepatic stellate cells ([@B16]) and macrophage-like cells ([@B57]), but the most comprehensive analysis was done for the monocytic cell line THP-1 ([@B22]; [@B36]). After stimulation with VDR ligand in all these *in vitro* cell culture models some 5,000--20,000 genomic binding sites were observed, which is a 2- to 10-fold increase compared to the respective basal condition. Interestingly, the VDR cistrome in THP-1 cells contains a few hundred persistent loci that stay always occupied ([@B36]). These primary contacts of the human genome with 1,25(OH)~2~D~3~ are considered as "hotspots" of vitamin D signaling that coordinate the functional consequences of a stimulation with vitamin D over time. In addition, there are transient VDR binding loci that modulate the response of the epigenome to vitamin D and support persistent VDR sites. Thus, the genome-wide, ligand-induced binding of VDR to its preferred loci represents the most prominent epigenome-wide effect of vitamin D.

![Vitamin D signaling in the context of chromatin. Chromatin within the nucleus forms a 3D architecture **(left)**. Two CTCF proteins bound at adjacent chromatin boundaries form a complex defining a TAD **(right bottom)**. Enhancers and TSS regions that are located within the same TAD can get into physical contact within DNA looping **(right top)**. 1,25(OH)~2~D~3~-activated VDR forms a heterodimeric complex with RXR on enhancer regions carrying appropriate binding sites. In this way, chromatin modifiers are activated that change histone marks (shown here are H3K4me3 modifications marking active TSS regions and H3K27ac indicating active chromatin) and the mediator complex forms a bridge to the basal transcriptional machinery with RNA polymerase II as its core. This finally leads to mRNA transcription of respective vitamin D target genes.](fphys-10-00194-g001){#F1}

The Chromatin Model of Vitamin D Signaling
==========================================

Chromatin is the complex of genomic DNA with nucleosomes that stabilizes the epigenetic landscape of a differentiated cell ([@B2]). By default chromatin largely restricts the access of transcription factors to promoter and enhancer regions, so that per cell type only some 100--200,000 genomic regions are accessible ([@B55]). The epigenome is represented by (i) more than 100 post-translational modifications, such as acetylations and methylations, of the four nucleosome-forming histone proteins ([@B11]), (ii) DNA methylation, preferentially within so-called "CpG islands" ([@B15]) and iii) higher order chromatin structures, such as the three-dimensional organization of the genome into topologically associated domains (TADs) ([@B12]). Importantly, the epigenome is dynamic, i.e., it can be modulated by environmental signals that influence chromatin modifying enzymes, such as DNA methyltransferases, histone acetyl- and methyltransferases as well as histone deacetylases and demethylases, that write, read or erase marks on genomic DNA and histone proteins.

For the transcription of a gene it is essential that the genomic regions of both its transcription start site (TSS) and the binding sites of the transcription factors controlling the activity of RNA polymerase II, referred to as enhancers, are located within accessible chromatin ([@B10]). Open chromatin can be measured by the method formaldehyde-assisted isolation of regulatory elements sequencing (FAIRE-seq) and some 9,000 sites of accessible chromatin were found to be sensitive to vitamin D stimulation ([@B48]). A prominent marker of active chromatin at enhancer regions is the histone modification H3K27ac, while H3K4me3 labels TSS regions. Interestingly, both types of histone markers are sensitive to vitamin D ([@B39]).

In human, most epigenome-wide data on 1,25(OH)~2~D~3~ and its receptor VDR have been collected in cells of the innate and adaptive immune system ([@B5]). Accordingly, the chromatin model of vitamin D signaling, describing the sequential process of vitamin D target gene activation, has been developed based on epigenome- and transcriptome-wide data obtained primarily in THP-1 cells ([@B7]). As outlined above, the first event in vitamin D signaling is the genome-wide binding of ligand-activated VDR molecules to enhancer regions that carry suitable binding motifs and are located within accessible chromatin. With the help of pioneer factors, such as PU.1 ([@B49]), CEBPA ([@B40]) and GABPA ([@B50]) VDR increases the accessibility of chromatin at and around these enhancer regions. This epigenomic process also involves local changes in the intensity of H3K27ac histone markers marking active chromatin at enhancer and TSS regions ([@B39]). Via DNA looping VDR-bound, activate enhancer regions contact TSS regions within the same TAD and trigger the transcription of the respective vitamin D target genes ([Figure 1](#F1){ref-type="fig"}).

TADs range in size from 30 kb to 3 Mb and subdivide the human genome into at least 2,000 functionally independent domains ([@B17]). Enhancer-TSS contacts are very likely within the same TAD, while interaction with genomic regions outside of a TAD are inhibited by insulating TAD borders that are marked by the transcription factor CTCF ([@B1]; [Figure 1](#F1){ref-type="fig"}). Thus, VDR-bound enhancers can only modulate the transcription of those genes, which are located within the same TAD. Accordingly, the linear distance between a VDR site within an enhancer and its target TSS is limited by the size of the respective TAD but it can be many hundred kb (see [Supplementary Table S1](#SM2){ref-type="supplementary-material"} for examples).

Interestingly, in THP-1 cells 1,25(OH)~2~D~3~ stimulation significantly (*p* \< 0.05) affects the binding strength of CTCF to TAD anchors making some 600 TADs sensitive of vitamin D ([@B35]). Looping of activated DNA-bound VDR to a TSS leads at these promoter regions to an increase in chromatin accessibility as well as of H3K27ac and H3K4me3 marks ([@B48]; [@B40]). All these vitamin D-triggered changes in the local chromatin structure at enhancer and promoter regions finally lead to the activation of RNA polymerase II assembled on the respective TSSs and the start of mRNA synthesis. Thus, vitamin D signaling involves a number of epigenome-wide events before there are responses on the level of the transcriptome.

The chromatin model of vitamin D signaling explains the activation of primary vitamin D target genes, which are the focus of this review. However, there is also a large number of secondary vitamin D target genes, the activation of which do not directly require VDR as a central protein. The activity of transcription factors other than VDR and/or chromatin modifying proteins, which are encoded by primary targets of vitamin D, mediate the activation of these secondary vitamin D target genes. Examples are the transcription factors BCL6, NFE2, POU4F2, and ELF4, which are in THP-1 cells primary vitamin D target genes ([@B38]).

Vitamin D Target Genes in THP-1 Cells
=====================================

Since more than two decades many research groups have used the human acute monocytic leukemia cell line THP-1 ([@B56]) as a model system for investigating the effects of vitamin D-triggered physiological processes in the context of innate immunity. A PubMed search (September 19, 2018) with the keywords "Vitamin D AND THP-1" revealed 161 publications, which were manually inspected whether they report in undifferentiated THP-1 cells statistically significant effects of 1,25(OH)~2~D~3~ on the mRNA expression of individual genes, as measured by qPCR, or of gene sets, as monitored by microarrays or RNA sequencing (RNA-seq). The attribute "undifferentiated THP-1 cells" was fulfilled by 53 articles, 19 of which were not considered, since they used less quantitative assays, such as Northern blotting, or focused on changes in protein expression by flow cytometry or Western blotting. The remaining 34 publications reported effects of 1,25(OH)~2~D~3~ on enhancer/TSS regions and/or mRNA expression of in total 107 different genes ([Table 1](#T1){ref-type="table"}). In reference to a re-analyzed RNA-seq time course ([@B48]; [@B36]; [@B40]), of these genes were classified as primary vitamin D targets, i.e., their expression changed significantly (*p* \< 0.05) within 4 h after onset of stimulation with 1,25(OH)~2~D~3~, while 28 genes were secondary vitamin D targets. However, the transcriptome-wide assay failed to confirm 15 genes, i.e., 14% of all, as vitamin D target genes. This reflects a well-known discrepancy, which is based mainly on different threshold settings and more strict statistical approaches of the transcriptome-wide method.

###### 

Vitamin D target genes.

  Gene         Primary?   Type(s) of assays                                Citation
  ------------ ---------- ------------------------------------------------ ----------
  *CAMP*       Yes        qPCR                                             [@B29]
  *CYP24A1*    --         qPCR                                             [@B29]
  *CYP24A1*    --         qPCR                                             [@B63]
  *CYP27B1*    --         qPCR                                             [@B63]
  *CD14*       Yes        qPCR                                             [@B32]
  *ITGAM*      Yes        qPCR                                             [@B32]
  *ALOX5*      No         qPCR                                             [@B30]
  *CAMP*       Yes        qPCR                                             [@B30]
  *CD14*       Yes        qPCR                                             [@B30]
  *CYP24A1*    *--*       qPCR                                             [@B30]
  *FANCE*      Yes        ChIP-seq & FAIRE-seq display, qPCR               [@B51]
  *HBEGF*      Yes        ChIP-seq & FAIRE-seq display, qPCR               [@B51]
  *NFKBIA*     Yes        ChIP-seq & FAIRE-seq display, qPCR               [@B51]
  *PDCD1LG2*   Yes        ChIP-seq & FAIRE-seq display, qPCR               [@B51]
  *TMEM37*     Yes        ChIP-seq & FAIRE-seq display, qPCR               [@B51]
  *BHLHE40*    *--*       ChIP-seq & FAIRE-seq display, qPCR               [@B52]
  *CAMP*       Yes        ChIP-seq & FAIRE-seq display, qPCR               [@B46]
  *CD93*       Yes        ChIP-seq & FAIRE-seq display, qPCR               [@B46]
  *DUSP10*     Yes        ChIP-seq & FAIRE-seq display, qPCR               [@B46]
  *HBEGF*      Yes        ChIP-seq & FAIRE-seq display, qPCR               [@B46]
  *NFKBIA*     Yes        ChIP-seq & FAIRE-seq display, qPCR               [@B46]
  *THBD*       Yes        ChIP-seq & FAIRE-seq display, qPCR               [@B46]
  *IL1B*       No         qPCR, microarray                                 [@B59]
  *ASAP2*      Yes        ChIP-seq display, qPCR                           [@B53]
  *YWHAQ*      No         ChIP-seq display, qPCR                           [@B53]
  *SEPT3*      Yes        ChIP-seq & FAIRE-seq display, qPCR               [@B47]
  *SFT2D1*     Yes        ChIP-seq & FAIRE-seq display, qPCR               [@B47]
  *SP100*      Yes        ChIP-seq & FAIRE-seq display, qPCR               [@B47]
  *ZFP36*      Yes        ChIP-seq & FAIRE-seq display, qPCR               [@B47]
  *TNF*        *--*       qPCR                                             [@B44]
  *ASAP2*      Yes        ChIP-seq display                                 [@B57]
  *CAMP*       Yes        ChIP-seq display                                 [@B57]
  *DENND6B*    Yes        ChIP-seq display                                 [@B57]
  *NINJ1*      Yes        ChIP-seq display                                 [@B57]
  *PTGER3*     --         ChIP-seq display                                 [@B57]
  *SP100*      Yes        ChIP-seq display                                 [@B57]
  *TBP*        No         ChIP-seq display                                 [@B57]
  *TRAK1*      Yes        ChIP-seq display                                 [@B57]
  *TLR10*      *--*       qPCR                                             [@B58]
  *CD97*       Yes        ChIP-seq & FAIRE-seq display, qPCR               [@B62]
  *LRRC8A*     Yes        ChIP-seq & FAIRE-seq display, qPCR               [@B62]
  *NRIP1*      Yes        ChIP-seq & FAIRE-seq display, qPCR               [@B62]
  *SLC37A2*    Yes        ChIP-seq & FAIRE-seq display, qPCR               [@B62]
  *TREM1*      Yes        qPCR                                             [@B27]
  *BCL6*       Yes        Microarray, qPCR                                 [@B38]
  *ELF4*       Yes        ChIP-seq & FAIRE-seq display, microarray, qPCR   [@B38]
  *FUCA1*      Yes        ChIP-seq & FAIRE-seq display, microarray, qPCR   [@B38]
  *ITGAM*      Yes        ChIP-seq & FAIRE-seq display, microarray, qPCR   [@B38]
  *LPGAT1*     No         ChIP-seq & FAIRE-seq display, microarray, qPCR   [@B38]
  *LPP*        *--*       Microarray, qPCR                                 [@B38]
  *LRRC25*     Yes        ChIP-seq & FAIRE-seq display, microarray, qPCR   [@B38]
  *NFE2*       Yes        ChIP-seq & FAIRE-seq display, microarray, qPCR   [@B38]
  *POU4F2*     Yes        ChIP-seq & FAIRE-seq display, microarray, qPCR   [@B38]
  *RTP4*       *--*       Microarray, qPCR                                 [@B38]
  *SHE*        Yes        ChIP-seq & FAIRE-seq display, microarray, qPCR   [@B38]
  *SLC45A3*    No         ChIP-seq & FAIRE-seq display, microarray, qPCR   [@B38]
  *TMEM243*    No         ChIP-seq & FAIRE-seq display, microarray, qPCR   [@B38]
  *TREM1*      Yes        ChIP-seq & FAIRE-seq display, microarray, qPCR   [@B38]
  *CD274*      Yes        ChIP-seq & FAIRE-seq display                     [@B35]
  *CYP26B1*    Yes        ChIP-seq & FAIRE-seq display                     [@B35]
  *EPB41L1*    No         ChIP-seq & FAIRE-seq display                     [@B35]
  *PLGRKT*     No         ChIP-seq & FAIRE-seq display                     [@B35]
  *SIRT4*      Yes        ChIP-seq & FAIRE-seq display                     [@B35]
  *APBB3*      No         ChIP-seq & FAIRE-seq display                     [@B34]
  *CCL2*       Yes        ChIP-seq & FAIRE-seq display                     [@B34]
  *CD14*       Yes        ChIP-seq & FAIRE-seq display                     [@B34]
  *FCER2*      No         ChIP-seq & FAIRE-seq display                     [@B34]
  *HBEGF*      Yes        ChIP-seq & FAIRE-seq display                     [@B34]
  *PFDN1*      Yes        ChIP-seq & FAIRE-seq display                     [@B34]
  *SLC35A4*    Yes        ChIP-seq & FAIRE-seq display                     [@B34]
  *SRA1*       Yes        ChIP-seq & FAIRE-seq display                     [@B34]
  *WDR55*      Yes        ChIP-seq & FAIRE-seq display                     [@B34]
  *ALOX5*      No         qPCR, RNA-seq                                    [@B48]
  *ASAP2*      Yes        qPCR, RNA-seq                                    [@B48]
  *CAMP*       Yes        qPCR, RNA-seq                                    [@B48]
  *CD14*       Yes        qPCR, RNA-seq                                    [@B48]
  *ELL*        Yes        qPCR, RNA-seq                                    [@B48]
  *FANCE*      Yes        qPCR, RNA-seq                                    [@B48]
  *FBP1*       Yes        qPCR, RNA-seq                                    [@B48]
  *G0S2*       Yes        qPCR, RNA-seq                                    [@B48]
  *HBEGF*      Yes        qPCR, RNA-seq                                    [@B48]
  *HTT*        Yes        ChIP-seq & FAIRE-seq display, RNA-seq            [@B48]
  *MPC1*       No         qPCR, RNA-seq                                    [@B48]
  *MYC*        *--*       qPCR, RNA-seq                                    [@B48]
  *NOD2*       Yes        ChIP-seq & FAIRE-seq display, RNA-seq            [@B48]
  *PPARGC1B*   Yes        qPCR, RNA-seq                                    [@B48]
  *THBD*       Yes        qPCR, RNA-seq                                    [@B48]
  *TMEM37*     Yes        qPCR, RNA-seq                                    [@B48]
  *ZFP36*      Yes        qPCR, RNA-seq                                    [@B48]
  *CYTH4*      Yes        ChIP-seq & FAIRE-seq display                     [@B7]
  *ELFN2*      Yes        ChIP-seq & FAIRE-seq display                     [@B7]
  *AKIRIN1*    Yes        ChIP-seq & FAIRE-seq display                     [@B49]
  *BDH1*       No         ChIP-seq & FAIRE-seq display                     [@B49]
  *CAMP*       Yes        ChIP-seq & FAIRE-seq display                     [@B49]
  *CD14*       Yes        ChIP-seq & FAIRE-seq display                     [@B49]
  *CD226*      No         ChIP-seq & FAIRE-seq display                     [@B49]
  *CD274*      Yes        ChIP-seq & FAIRE-seq display, qPCR               [@B49]
  *CD36*       Yes        qPCR                                             [@B49]
  *CD97*       Yes        ChIP-seq & FAIRE-seq display                     [@B49]
  *DRAM1*      No         ChIP-seq & FAIRE-seq display                     [@B49]
  *DUSP10*     Yes        ChIP-seq & FAIRE-seq display                     [@B49]
  *FANCE*      Yes        qPCR                                             [@B49]
  *FHL1*       No         ChIP-seq & FAIRE-seq display                     [@B49]
  *MYO7B*      No         ChIP-seq & FAIRE-seq display                     [@B49]
  *PCTP*       No         ChIP-seq & FAIRE-seq display                     [@B49]
  *PPARGC1B*   Yes        ChIP-seq & FAIRE-seq display                     [@B49]
  *RTCB*       *--*       ChIP-seq & FAIRE-seq display                     [@B49]
  *SLC37A2*    Yes        ChIP-seq & FAIRE-seq display                     [@B49]
  *SPI1*       *--*       qPCR                                             [@B49]
  *AGPAT1*     Yes        ChIP-seq & FAIRE-seq display                     [@B8]
  *CD14*       Yes        ChIP-seq & FAIRE-seq display                     [@B39]
  *CLMN*       Yes        ChIP-seq & FAIRE-seq display                     [@B39]
  *TMEM37*     Yes        ChIP-seq & FAIRE-seq display                     [@B39]
  *CD14*       Yes        ChIP-seq & FAIRE-seq display                     [@B50]
  *COQ3*       No         ChIP-seq & FAIRE-seq display                     [@B50]
  *DND1*       Yes        ChIP-seq & FAIRE-seq display                     [@B50]
  *NDUFA2*     No         ChIP-seq & FAIRE-seq display                     [@B50]
  *PSMB1*      No         ChIP-seq & FAIRE-seq display                     [@B50]
  *SLC25A15*   No         ChIP-seq & FAIRE-seq display                     [@B50]
  *SLC52A2*    No         ChIP-seq & FAIRE-seq display                     [@B50]
  *TBP*        No         ChIP-seq & FAIRE-seq display                     [@B50]
  *TMCO6*      Yes        ChIP-seq & FAIRE-seq display                     [@B50]
  *WDR55*      Yes        ChIP-seq & FAIRE-seq display                     [@B50]
  *ZNF44*      Yes        ChIP-seq & FAIRE-seq display                     [@B50]
  *ACSL1*      Yes        ChIP-seq & FAIRE-seq display, RNA-seq            [@B40]
  *CD14*       Yes        ChIP-seq & FAIRE-seq display, RNA-seq            [@B40]
  *CDA*        No         ChIP-seq & FAIRE-seq display, RNA-seq            [@B40]
  *FBP1*       Yes        ChIP-seq & FAIRE-seq display, RNA-seq            [@B40]
  *G0S2*       Yes        ChIP-seq & FAIRE-seq display, RNA-seq            [@B40]
  *GLIPR1*     Yes        ChIP-seq & FAIRE-seq display, RNA-seq            [@B40]
  *INSR*       Yes        ChIP-seq & FAIRE-seq display, RNA-seq            [@B40]
  *ITSN1*      Yes        ChIP-seq & FAIRE-seq display, RNA-seq            [@B40]
  *KLHDC8B*    No         ChIP-seq & FAIRE-seq display, RNA-seq            [@B40]
  *NFKBIA*     Yes        ChIP-seq & FAIRE-seq display, RNA-seq            [@B40]
  *PNPLA1*     No         ChIP-seq & FAIRE-seq display, RNA-seq            [@B40]
  *SERINC2*    Yes        ChIP-seq & FAIRE-seq display, RNA-seq            [@B40]
  *SOAT1*      No         ChIP-seq & FAIRE-seq display, RNA-seq            [@B40]
  *SSH1*       Yes        ChIP-seq & FAIRE-seq display, RNA-seq            [@B40]

List of 34 studies that investigated vitamin D target genes in undifferentiated THP-1 cells by the indicated types of assays. The information whether a gene is a primary target (yes), secondary target (no) or not detected (-) by a RNA-seq time course is derived from a re-analysis (

Neme et al., 2017

) of the original dataset from

Seuter et al. (2016)

.

Next, all publically available transcriptome-wide data for 1,25(OH)~2~D~3~-stimulated, undifferentiated THP-1 cells were compared. A search of the Gene Expression Omnibus^[2](#fn02){ref-type="fn"}^ resulted in the microarray datasets GSE60102 ([@B22]) and GSE52819 ([@B59]) as well as in the RNA-seq datasets GSE69284 ([@B48]) and GSE119556 ([@B40]). In all four datasets undifferentiated THP-1 cells had been stimulated for 24 h with 1,25(OH)~2~D~3~. The comparison of the 3,372 significantly (*p* \< 0.05) regulated genes in the microarray from 2011 ([@B22]) and the 4,532 genes in the microarray from 2013 ([@B59]) indicated 1,227 common genes ([Supplementary Figure S1](#SM1){ref-type="supplementary-material"}). 695 of the latter matched with the 3,650 genes reported in the re-analyzed RNA-seq dataset from 2016 ([@B48]; [@B36]) and 268 with the 951 genes identified in the RNA-seq dataset from 2018 ([@B40]). Furthermore, both RNA-seq datasets had 273 overlapping genes, 126 of which belonged to the 1,227 common genes found by microarrays.

Taken together, the four transcriptome-wide dataset agreed on 126 genes that were regulated within 24 h after a stimulation with 1,25(OH)~2~D~3~. Although all four experimental series had been performed in three biological repeats and only significantly (*p* \< 0.05) modulated genes were considered, the rather low number of common genes indicates that the fluctuation in low expressed, moderately regulated genes was very high.

Transcriptional Response of Vitamin D Target Genes
==================================================

The recent 1,25(OH)~2~D~3~-dependent transcriptome analysis ([@B40]) identified in THP-1 cells 951 genes as vitamin D targets, 273 of which overlapped with the re-analyzed earlier RNA-seq dataset ([@B48]; [@B36]; [Figure 2A](#F2){ref-type="fig"}). The latter dataset allowed assigning 189 of the 273 genes (69%) as primary vitamin D targets ([Supplementary Table S1](#SM2){ref-type="supplementary-material"}). Interestingly, 59 (75% primary) of the 273 common genes had already been characterized by single-gene approaches ([Table 1](#T1){ref-type="table"}). From the 126 genes that were also found by microarrays about the same proportion (72%) were primary vitamin D targets ([Figure 2A](#F2){ref-type="fig"}).

![Gene ontology analysis. The most recent 1,25(OH)~2~D~3~-dependent transcriptome dataset of THP-1 cells ([@B40]) identified 951 genes, 273 of which overlap with the re-analyzed first RNA-seq dataset ([@B48]; [@B36]) **(A)**. 69% of the 273 genes are primary vitamin D targets (189 genes listed in [Supplementary Table S1](#SM2){ref-type="supplementary-material"}), while from the 126 genes that were also found by microarrays 72% are primary vitamin D targets. Gene ontology analysis using the webtool *Enrichr* ([@B14]) was performed for the lists of 951, 273, and 126 members and indicated that the top five biological pathways for each of the three gene sets relate to innate immunity **(B)**.](fphys-10-00194-g002){#F2}

The 189 primary vitamin D target genes ([Figure 2A](#F2){ref-type="fig"}) were classified by the fold change (FC) of their mRNA expression after 1,25(OH)~2~D~3~ stimulation for 24 h ([Supplementary Figure S2](#SM1){ref-type="supplementary-material"}). The six genes *CD14* (encoding for a toll-like receptor co-receptor), *ORM1* (encoding for an acute phase plasma protein), *CAMP, FBP1* (encoding for a glucose metabolizing enzyme), *CYP26B1* (encoding for an enzyme metabolizing retinoids) and *TSPAN18* (encoding for a membrane protein with unclear function) showed a FC larger than 40 and form group A. The FC of further 13 genes composing group B was in the range of 10 to 40, while the large group C comprised 170 genes displaying a FC below 10. Only 5 of the 189 primary vitamin D target genes are down-regulated, while nearly half of all secondary vitamin D target genes are down-regulated ([@B34]). Thus, in contrast to up-regulation, the mechanism of down-regulation of vitamin D target genes is mostly an indirect, multi-step process.

Functional Profile of Vitamin D Target Genes
============================================

The biologically most important question of the transcriptome-wide analysis was, how the action of the complete set of vitamin D target genes translates into physiological functions of human monocytes. Therefore, gene ontology analysis was applied, in order to identify statistically significant overrepresentation of vitamin D target genes in biological pathways. Using the webtool *Enrichr* ([@B14]) for the gene lists with 951, 273, and 126 members ([Figure 2A](#F2){ref-type="fig"}) provided the result that the top five biological pathways, such as "neutrophil activation," "positive regulation of TNF production," "inflammatory response," "neutrophil degranulation," "negative regulation of T cell proliferation" and "positive regulation of cytokine secretion," related for each of the three gene sets to key functions in innate immunity ([Figure 2B](#F2){ref-type="fig"}). This result could have been expected, since monocytes represent the major cell type of the innate immune system. Nevertheless, it is important to confirm that the key immune-related functions of monocytes are supported by vitamin D.

In summary, independent of the size of the tested target gene set, gene ontology analysis indicates that the modulation of innate immunity is the main physiological outcome of a vitamin D stimulation of human monocytes.

Classification of Primary Vitamin D Target Genes
================================================

Each of the 189 primary vitamin D target genes ([Supplementary Table S1](#SM2){ref-type="supplementary-material"}) was manually inspected for the epigenomic profile at its TSS and enhancer regions, such as (i) occurrence of H3K4me3 and H3K27ac marks, (ii) binding of VDR, PU.1 and CEBPA as well as (iii) the significant (*p* \< 0.05) modulation of both type of datasets by 1,25(OH)~2~D~3~. The whole TAD region of each primary target gene was screened for the most prominent enhancer. For 17 genes the enhancer was found in a distance of below 1 kb from the TSS, while in contrast for 23 genes it located more than 100 kb apart ([Supplementary Table S1](#SM2){ref-type="supplementary-material"}). Importantly, 160 of the 189 genes showed H3K4me3 marks at their TSS regions and could be segregated into four classes ([Supplementary Table S1](#SM2){ref-type="supplementary-material"} and [Figure 3](#F3){ref-type="fig"}), which were defined as follows: VDR bound to the enhancer regions of each of these 160 genes, but only the 82 genes of classes 1 and 2 displayed VDR binding also to their TSS regions, while for the 78 genes of classes 3 and 4 no VDR was detected at their promoters. In addition to genes with enhancer regions close to their promoters (82% of which are class 1 genes), VDR could be detected at TSS regions, because it is assumed to loop from an enhancer region rather than due to direct promoter binding. Thus, probably on class 3 and 4 genes no VDR was detected, because the protein did not make long and frequent enough contacts, in order to create at the respective TSS regions a significant mark in the VDR cistrome. However, 1,25(OH)~2~D~3~-triggered increases of H3K4me3 marks at TSS regions of 56 class 3 and 4 genes provided at least indirect evidence for a looping of enhancer-bound VDR to these promoter regions.

![Classification of primary vitamin D target genes. The 160 primary vitamin D target genes that show H3K4me3 marks at their TSS regions can be segregated into four classes. The structure of the genes into TSS and enhancer regions is schematically depicted. Genes of classes 1 and 2 display VDR binding to their TSS regions, while for those of classes 3 and 4 no VDR binding can be detected. The 59 genes of class 1 and the 52 genes of class 3 have significant (*p* \< 0.05) effects of 1,25(OH)~2~D~3~ on H3K4me3, H3K27ac, VDR, PU.1 and/or CEBPA binding strength on their enhancer region, while this is not observed for the 23 genes of class 2 and the 26 genes of class 4. In addition, for the respective classes the distribution of the genes of into the fold change (FC) groups A, B and C ([Supplementary Figure S2](#SM1){ref-type="supplementary-material"}) as well as the average FC is indicated.](fphys-10-00194-g003){#F3}

The 59 genes of class 1 were distinguished from the 23 genes of class 2 by experiencing significant (*p* \< 0.05) effects of ligand on the intensity of H3K4me3 and H3K27ac marks or the binding strength of VDR, PU.1 and/or CEBPA at their enhancer regions ([Figure 3](#F3){ref-type="fig"}). By the same kind of 1,25(OH)~2~D~3~-sensitivity at their enhancer regions the 52 genes of class 3 differed from the 26 genes of class 4. Representative examples for the differential epigenomic profiles at enhancer and TSS regions are the regulatory scenarios of the class 1 gene *TMEM37* (encoding for a stabilizer of calcium channels), the class 2 gene *LILRB4* (encoding for a membrane receptor), the class 3 gene *TFE3* (encoding for a transcription factor) and the class 4 gene *CYP26B1* ([Supplementary Figure S3](#SM1){ref-type="supplementary-material"}). In contrast, for 29 genes no specific epigenomic pattern on their TSS and enhancer regions had been detected, i.e., they remain unclassified for their epigenomic profile ([Supplementary Table S1](#SM2){ref-type="supplementary-material"}).

The 59 genes of class 1 showed with 11.24 the highest average FC, because three of them belong to the highly up-regulated group A and six to the strongly up-regulated group B ([Figure 3](#F3){ref-type="fig"}). Second ranking in average FC (6.69) were the 26 genes of class 4, since they comprise one group A gene and two group B genes. In contrast, the 52 class 3 genes averaged only in a FC of 3.67 (two group B genes and 50 moderately regulated group C genes) and the 23 class 2 gene even only in an average FC of 3.53 (one group B gene and 22 group C genes).

Taken together, 160 of the 189 primary vitamin D target genes could be segregated into four classes by the epigenomic profile of their enhancer and TSS regions. The key distinguishing protein of the respective gene regulatory scenarios was VDR bound to TSS and enhancer regions and being supported at enhancers by the pioneer transcription factors PU.1 and CEBPA.

Relation of Gene Regulatory Scenarios to Biological Function
============================================================

The integration of the transcriptome- and epigenome-wide datasets available for vitamin D-triggered human monocytes can be summarized as outlined in [Figure 4](#F4){ref-type="fig"}. On the transcriptome-level, a stimulation of THP-1 cells with 1,25(OH)~2~D~3~ has significant (*p* \< 0.05) direct effects on the expression of 189 genes, 184 of which are up-regulated ([Supplementary Table S1](#SM2){ref-type="supplementary-material"}). The proteins encoded by these genes mainly act as enzymes (20%), receptors (10%) and transporters (9%) and their most prominent locations are membranes (46%) and the nucleus (19%). Nearly a fourth (23.8%) of these primary vitamin D target genes are directly involved in the function of the immune system. On the epigenome level, 160 of the 189 genes can be classified into four gene regulatory scenarios, while 29 genes (15%) remain unclassified. The 82 genes with VDR binding at their TSS region show with 29.3% a higher rate of immune system related function than the 78 genes without detectable VDR (19.2%). Accordingly, the main characteristic of the 59 class 1 genes is the relation of their function to the immune system. In contrast, in absence of significant effects of 1,25(OH)~2~D~3~ on enhancer regions, as it applies for classes 2 and 4, preferentially genes with metabolic functions are found.

![Integration of gene regulatory scenarios with biological function. The main relations between the epigenomic profiles of primary vitamin D target genes and the function, cellular location and relation to immunity of their encoded proteins is outlined. More details are provided in the text.](fphys-10-00194-g004){#F4}

In summary, immune system-related genes of class 1 are supported by a gene regulatory scenario that allows a prominent up-regulation by vitamin D, while genes related to cellular metabolism show less vitamin D sensitive epigenomic profiles.

Future Perspective: Translation to Primary Cells
================================================

In the vitamin D intervention study VitDbol (NCT02063334, [ClinicalTrials.gov](https://clinicaltrials.gov)) healthy human adults were treated once with high dose of vitamin D~3~ (2,000 μg) and blood samples were taken before and 24 h later ([@B60]). Peripheral blood mononuclear cells (PBMCs, a mixture of the vitamin D-responsive cell types monocytes, T and B lymphocytes) were isolated in less than an hour after drawing blood, i.e., the epigenome and transcriptome status of the cells was as close as possible to the *in vivo* situation ([@B6]). Excluding any further *in vitro* culture, RNA and chromatin were prepared, in order to test changes in gene expression by qPCR ([@B60]) and RNA-seq ([@B37]) as well as alterations in chromatin accessibility at selected genomic regions ([@B54]) and genome-wide ([@B13]). Based on five tested individuals the expression of 702 genes changed significantly (*p* \< 0.05) in response to vitamin D~3~ ([@B37]), 26% of which were also observed in THP-1 cells as vitamin D target genes ([@B36]). Although the latter genes were primarily secondary targets, it indicates that the response of PBMCs *in vivo* to a vitamin D~3~ bolus resembles that of THP-1 cells *in vitro* to a 1,25(OH)~2~D~3~ bolus. Similarly, the vitamin D~3~ bolus significantly (*p* \< 0.05) changes *in vivo* the chromatin accessibility at 853 genomic regions ([@B13]), 87% of which were also 1,25(OH)~2~D~3~ responsive in THP-1 cells ([@B48]).

Taken together, there is reasonable overlap in the transcriptome- and epigenome-wide vitamin D response of PBMCs *in vivo* and THP-1 cells *in vitro*, i.e., principles of vitamin D signaling described in this review for THP-1 cells may also be extrapolated to primary cells, such as PBMCs. Primary monocytes would be most appropriate cellular target, for which, however, no vitamin D-triggered epigenome-wide data exists.

Conclusion
==========

To date, most epigenome- and transcriptome-wide data are available for the actions of vitamin D in cells of the hematopoietic system ([@B5]). The integration of these large datasets led to the chromatin model of vitamin D signaling ([@B7]), which was extended in this summary of recent data by the introduction of four different classes of primary vitamin D target genes. The respective gene regulatory scenarios distinguish prominent vitamin D response of genes related to immune function and moderate response of genes involved in cellular metabolism.
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1,25(OH)~2~D~3~

:   1α,25-dihydroxyvitamin D~3~

CAMP

:   cathelicidin antimicrobial peptide

CD14

:   CD14 molecule

CEBPA

:   CCAAT/enhancer binding protein alpha

ChIP-seq

:   chromatin immunoprecipitation sequencing

CTCF

:   CCCTC-binding factor

CYP26B1

:   cytochrome P450 family 26 subfamily B member 1

DR3

:   direct repeat spaced by 3 nucleotides

FAIRE-seq

:   formaldehyde-assisted isolation of regulatory elements sequencing

FBP1

:   fructose-bisphosphatase 1

FC

:   fold change

IGV

:   Integrative Genomics Viewer

LD

:   ligand-dependent

LILRB4

:   leukocyte immunoglobulin like receptor B4

ORM1

:   orosomucoid 1

PBMC

:   peripheral blood mononuclear cells

PU.1

:   purine-rich box 1

RNA-seq

:   RNA sequencing

RXR

:   retinoid X receptor

Spi-1 proto-oncogene

:   (official gene symbol: *SPI1*)

TAD

:   topologically associated domain

TFE3

:   transcription factor binding to IGHM enhancer 3

TMEM37

:   transmembrane protein 37

TSPAN18

:   tetraspanin 18

TSS

:   transcription start site

VDR

:   vitamin D receptor
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